Avita Medical Inc. (NASDAQ:RCEL) Given Consensus Rating of “Hold” by Analysts

Shares of Avita Medical Inc. (NASDAQ:RCEL) have received a consensus recommendation of “Hold” from the six ratings firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $11.60.

A number of analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avita Medical in a report on Saturday, September 27th. D. Boral Capital reissued a “buy” rating and issued a $14.00 target price on shares of Avita Medical in a research report on Monday, September 15th. Lake Street Capital dropped their target price on shares of Avita Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. BTIG Research downgraded shares of Avita Medical from a “neutral” rating to a “sell” rating and set a $3.00 target price on the stock. in a research report on Friday, August 8th. Finally, Wall Street Zen downgraded shares of Avita Medical from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th.

Insider Buying and Selling at Avita Medical

In other news, Director Robert Mcnamara bought 10,000 shares of the company’s stock in a transaction dated Thursday, August 28th. The shares were acquired at an average cost of $4.50 per share, with a total value of $45,000.00. Following the completion of the transaction, the director directly owned 86,771 shares in the company, valued at approximately $390,469.50. The trade was a 13.03% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have purchased 24,000 shares of company stock valued at $113,660 over the last quarter. Company insiders own 2.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new position in shares of Avita Medical in the fourth quarter worth approximately $38,000. CWM LLC grew its position in Avita Medical by 1,099.5% during the first quarter. CWM LLC now owns 4,918 shares of the company’s stock valued at $40,000 after purchasing an additional 4,508 shares in the last quarter. GAMMA Investing LLC grew its position in Avita Medical by 688.9% during the first quarter. GAMMA Investing LLC now owns 6,374 shares of the company’s stock valued at $52,000 after purchasing an additional 5,566 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in Avita Medical during the first quarter valued at approximately $53,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Avita Medical during the second quarter valued at approximately $58,000. 27.66% of the stock is owned by hedge funds and other institutional investors.

Avita Medical Price Performance

NASDAQ RCEL opened at $5.54 on Friday. The company’s 50 day simple moving average is $5.09 and its 200 day simple moving average is $6.39. Avita Medical has a 12 month low of $3.60 and a 12 month high of $14.16. The company has a market capitalization of $147.47 million, a P/E ratio of -2.81 and a beta of 1.64.

Avita Medical (NASDAQ:RCEL) last released its earnings results on Thursday, August 7th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.12). Avita Medical had a negative return on equity of 632.62% and a negative net margin of 68.87%.The business had revenue of $18.42 million during the quarter, compared to the consensus estimate of $34.27 million. Avita Medical has set its FY 2025 guidance at EPS. On average, analysts anticipate that Avita Medical will post -0.95 earnings per share for the current year.

Avita Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.